TY - JOUR T1 - Antisense-Mediated Down-Regulation of the Human Huntingtin Gene JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 239 LP - 243 VL - 295 IS - 1 AU - Ruben J. Boado AU - Aleksey Kazantsev AU - Barbara L. Apostol AU - Leslie M. Thompson AU - William M. Pardridge Y1 - 2000/10/01 UR - http://jpet.aspetjournals.org/content/295/1/239.abstract N2 - The present study determines whether the expression of the huntingtin gene might be subject to antisense (AS)-mediated down-regulation. A series of AS oligodeoxynucleotides (ODNs) complementary to the huntingtin transcript [i.e., nucleotide (nt) −25 to 35] were designed and synthesized, and the AS efficacy was investigated by using a combination of in vitro transcription and translation to mimic in vivo conditions. An oligomer directed to nt −1 to 15 (ODN III) markedly reduced the incorporation of [3H]leucine into the huntingtin gene product in a dose-dependent manner (ED50 of ∼11.5 μM). ODNs that overlap with ODN III on both 5′- and 3′-flanking regions also produced translation arrest of the huntingtin protein; however, the AS-mediated effect of these ODNs represented ∼50% of the effect of ODN III. In contrast, an ODN directed to nt 19 to 35 had no AS effect. The efficacy of ODN III also was investigated in an inducible, stably transfected PC-12 cell line expressing a truncated huntingtin exon 1 protein. In accordance with the cell free translation studies, ODN III (1–10 μM) markedly decreased the abundance of the huntingtin-green fluorescence fusion protein to 40 to 46% of the control levels. In summary, a series of putative AS candidates were screened for down-regulation of the huntingtin gene, and an ODN molecule directed to the methionine initiation codon was identified with maximum AS effects. The American Society for Pharmacology and Experimental Therapeutics ER -